In this article, we are going to take a look at where Global Partners LP (NYSE:GLP) stands against other oil & gas stocks that are skyrocketing so far in 2025. The oil & gas sector has ...

Adam Gilden, MD, MSCE, is an associate director of the Obesity Medicine Fellowship at University of Colorado School of Medicine and associate director of the Colorado University Medicine Weight ...

The shopping and eating behaviors of consumers taking GLP-1 medications are poised to impact grocers in multiple ways as usage of the weight-loss drugs continues to rise, new research indicates. A new ...

One in eight. That's how many people living in the United States have taken some form of a glucagon-like peptide 1, otherwise known as a GLP-1, medication for weight loss and related conditions ...

As the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) continues to exponentially expand obesity treatment, concerns have arisen regarding their impact on nutrition in people who take ...

Havas is forging deeper into the GLP-1 space with a series of YouTube videos about the drug class and its impact on the world. The ad agency is pitching the series as both a science-led initiative ...

In short, LifeVantage is riding the coattails of Eli Lilly's (LLY) GLP-1 agonist blockbuster weight-loss drug Zepbound with its "MindBody GLP-1 System": The MindBody GLP-1 System was launched in ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

It’s a synthetic version of the hormone GLP-1, which helps regulate our metabolism and hunger. Semaglutide and other newer GLP-1 medications have proven to be far more effective at treating ...

Glucagon-like peptide-1 (GLP-1) receptor agonists, including those targeting additional pathways, help otherwise healthy people without diabetes shed pounds, albeit at the cost of some side effects, a ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making versions of one of its GLP-1 agonist drugs. The latest attempt focuses ...